Eef2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
eEF2 is a eukaryotic translation elongation factor involved in protein synthesis. It plays a critical role in delivering aminoacyl-tRNAs to the ribosome during the elongation phase of translation. Mutations or dysregulation of these translation factors are associated with various diseases including neurodegeneration, cancer, and ribosomopathies.
.infobox .infobox-protein
{
float: right;
width: 300px;
padding: 10px;
background: #f8f9fa;
border: 1px solid #ddd;
border-radius: 4px;
margin: 10px;
}
.infobox .infobox-protein th
{
background: #28a745;
color: white;
padding: 8px;
}
.infobox .infobox-protein td
{
padding: 6px;
}
eEF2 has a GTP-binding domain and four C-terminal alpha-helical domains. The protein undergoes large conformational changes during the translocation step.
eEF2 catalyzes the translocation of peptidyl-tRNA from the A-site to the P-site during protein synthesis. It is regulated by phosphorylation (by eEF2 kinase) in response to cellular stress. eEF2 is essential for synaptic plasticity and memory formation.
Dysregulated eEF2 phosphorylation has been observed in Alzheimer's disease, Parkinson's disease, and Huntington's disease. It affects synaptic protein synthesis.
eEF2 kinase inhibitors are being explored to enhance translation in neurodegeneration. The drug RXDX-103 (tamatinib) has been studied.
The study of Eef2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.